Drug updated on 9/4/2024
Dosage Form | Capsules (oral: 100 mg, 200 mg, 300 mg) |
Drug Class | Synthetic amino acid analogs |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of orthostatic dizziness and light-headedness or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Latest News
Summary
- Northera (droxidopa) is indicated for the treatment of orthostatic dizziness and light-headedness, or the "feeling that you are about to black out," in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- Pharmacologic treatments, including droxidopa, were effective in reducing Postural Orthostatic Tachycardia Syndrome (POTS) symptoms and increasing orthostatic tolerance, although the studies had small sample sizes (10-50 subjects).
- Droxidopa, midodrine, and pyridostigmine were noted as effective in preventing Orthostatic Hypotension (OH), with clonidine and beta-blockers used to treat Supine Hypertension (SH) without causing significant hypotension.
- No significant differences in effectiveness among different population types or subgroups were reported in the studies.
- There is no safety information available in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Northera (droxidopa) prescribing information. | 2019 | Lundbeck, Deerfield, IL |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Choices and challenges with drug therapy in postural orthostatic tachycardia syndrome: a systematic review. | 2023 | Cureus |
Prevention and management of supine hypertension in patients with orthostatic hypotension. | 2021 | American Journal of Therapeutics |